Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials. (17th November 2020)

• Record Type: Journal Article
• Authors: Samineni, Divya; Ding, Hao; Ma, Fang; Shi, Rong; Lu, Dan; Miles, Dale; Mao, Jialin; Li, Chunze; Jin, Jin; Wright, Matthew; Girish, Sandhya; Chen, Yuan
• Other Names: Arya Vikram guestEditor.; Venkatakrishnan Karthik guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 60(2020)Supplement 1
• Page Start: S120
• Page End: S131
• Publication Date: 2020-11-17
• Subjects: antibody‐drug conjugate -- drug‐drug interaction -- drug labeling -- model‐informed drug development -- physiologically based pharmacokinetics; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1718
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Model‐informed drug development (MIDD) has become an important approach to improving clinical trial efficiency, optimizing drug dosing, and proposing drug labeling in the absence of dedicated clinical trials. For the first time, we developed a physiologically based pharmacokinetic (PBPK) model‐based approach to assess CYP3A‐mediated drug‐drug interaction (DDI) risk for polatuzumab vedotin (Polivy), an anti‐CD79b‐vc‐monomethyl auristatin E (MMAE) antibody‐drug conjugate (ADC). The model was developed and verified using data from the existing clinical DDI study for brentuximab vedotin, a similar vc‐MMAE ADC. Analogous to the brentuximab vedotin clinical study, polatuzumab vedotin at the proposed labeled dose was predicted to have a limited drug interaction potential with strong CYP3A inhibitor and inducer. Polatuzumab vedotin was also predicted to neither inhibit nor induce CYP3A. The present work demonstrated a high‐impact application using a PBPK MIDD approach to predict the CYP3A‐mediated DDI to enable drug labeling in the absence of any dedicated clinical DDI study. The key considerations for the PBPK report included in the Biologics License Application/Marketing Authorization Application submission, as well as the strategy and responses to address some of the critical and challenging questions from the health authorities following the submission are also discussed. Our experience and associated perspective using a PBPK approach to ultimately enable a drug interaction label claim for polatuzumab vedotin in lieu of a dedicated clinical DDI study, as well as the interactions with the regulatory agencies, further provides confidence in applying MIDD to accelerate the registration and approval of new drug therapies.